Higher interest rates and sustained inflation (due to 'Higher for Longer' rates and Iran War escalation) increase the cost of capital for R&D-heavy biotechnology companies like Champions Oncology, potentially impacting their ability to fund research, growth initiatives, and operational costs. This can also reduce investor appetite for growth stocks.

Geopolitical instability, such as the Iran War escalation and Strait of Hormuz closure, can create broader market uncertainty and lead to a 'risk-off' sentiment among investors. This could result in capital flowing out of smaller, potentially more volatile biotech stocks into safer assets, affecting CSBR's valuation and access to funding.

The ongoing Q1 2026 earnings season, particularly reports from other companies in the healthcare and biotechnology sectors, will influence overall investor sentiment. Positive or negative surprises from peers could create ripple effects, affecting investor confidence and the stock performance of Champions Oncology, especially given its own mixed recent earnings.